Albertsons Seeks $9.3 Billion From Kroger Over Failed Merger 
Philippines Current Account Deficit Seen at $19.1 Billion in 2026 
Syndax Stock Drops 15% After Axatilimab Trial Failure 
Trezor Cuts Reseller Network After Ledger Security Breach 
Gold Prices Rebound as Dollar Weakens Ahead of US Inflation Data 
NEAR Protocol Leads AI Crypto Rally Amid Fed Rate Hike Fears 
Asian Stocks Plunge as AI Chip Selloff Hits South Korea and Japan 
Trump Secures Russian Diesel Deal as US Fuel Prices Surge 
Bumble Shares Surge 50% on $1 Billion Buyout Talks 
UK Finance Minister Healey Calls for Fiscal Discipline Amid Global Risks 
Trump Defends Russian Diesel Deal Amid US Sanctions Backlash 
Tesla Holds $960 Million in Bitcoin as BTC Gains Top $710 Million 
Meta Launches Muse Wonder AI Models, Shares Rise 3.7% 
Most Americans Oppose Election Betting on Prediction Markets, Poll Finds 
Kalshi Seeks Sixth Circuit Review of Sports Betting Ruling 
Wall Street Ends Mixed as Investors Await CPI and Bank Earnings 
Oil Prices Surge Above $106 After Deadly Saudi Airport Attack 
Add as a preferred source on Google
Celltrion and Mirae Asset were said to have agreed on buying the largest stake in the UK-headquartered antibody-drug conjugates developer, Iksuda Therapeutics. Based on the report, the deal between the companies is worth $47 million.
The stake acquisition deal
As per The Korea Economic Daily, with its huge investment, Celltrion Inc. is expecting to expand its cancer drug line. The biopharmaceutical company headquartered in Incheon, South Korea, wants to develop more treatments in addition to its Truxima, a blood cancer drug, and Herzuma for breast cancer.
It was said that Iksuda has four ADC-based drugs that are already in pre-clinical development, including B-cell lymphomas. Celltrion can make use of these once the deal is fully completed.
ADC is an advanced technology that was created to specifically target a cancer cell. In any case, Celltrion and Mirae Asset have paid half of the investment price to the British biotech firm, and the rest of the payment will be delivered once agreed development milestones are reached.
"This stake investment will create synergy with our antibody treatments and add next-generation anticancer drugs to our pipeline," a Celltrion official said.
The benefits from the investments for Iksuda
Celltrion and Mirae Asset’s investment in Iksuda Therapeutics will make them the largest stakeholder in the UK-based company. The funding coming from the Korean firms will go to the development and advancement of Iksuda’s lead ADC assets and other technologies.
It was mentioned that Iksuda’s lead pre-clinical drug is called IKS03, and it is said to be a “best-in-class” CD19-targeted ADC candidate for B-cell cancers. Celltrion and Mirae’s multi-million investment will be used for IKSO3 to progress from its first human phase 1 clinical trial.
“This is a transformational investment milestone for Iksuda, enabling us to focus on the progression of our industry-leading ADC programs and bring them to the clinic, whilst supporting our commercial growth,” Iksuda Therapeutics CEO, Dr.Dave Simpson, said in a press release. “The funding not only reflects the potential of our technologies but also the unmatched expertise of the Iksuda team. We are grateful for the support of this group of investors and delighted to welcome them to the team.
